School of Anatomy, Physiology, and Human Biology, University of Western Australia, Crawley, Australia.
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Canada.
Trends Mol Med. 2016 Nov;22(11):935-945. doi: 10.1016/j.molmed.2016.09.001. Epub 2016 Sep 28.
Asthma is a lung disorder triggered by various airborne factors in susceptible individuals. Although generally controlled, asthma can be severe and difficult to treat. Presently, increasing numbers of pharmaceuticals capable of blocking or mimicking specific endogenous molecules are undergoing clinical trials in asthmatic individuals whose symptoms are poorly controlled despite adherence to guideline therapies. Unfortunately, only a few, meticulously selected patients have been found to minimally benefit. These findings not only confirm that the molecular pathogenesis of severe asthma is variable between patients but also suggest that each molecular defect is likely to contribute little on its own in each patient. We opine that therapies targeting a specific molecular defect are predestined to yield marginal effects in the treatment of severe asthma.
哮喘是一种由易感个体吸入的各种空气传播因子引发的肺部疾病。尽管通常可以控制，但哮喘可能很严重且难以治疗。目前，越来越多的能够阻断或模拟特定内源性分子的药物正在接受临床试验，这些药物用于治疗那些尽管遵循指南治疗但症状仍未得到良好控制的哮喘患者。不幸的是，仅发现少数经过精心挑选的患者有最小的获益。这些发现不仅证实了严重哮喘的分子发病机制在患者之间存在差异，而且还表明每个分子缺陷本身在每个患者中的作用都可能很小。我们认为，针对特定分子缺陷的治疗注定只能在严重哮喘的治疗中产生边际效果。
